Skip to content

Evaluation of Human Papillomavirus Vaccine Coverage in Girls and Young Women With Chronic Disease

Evaluation of Human Papillomavirus Vaccine Coverage in Girls and Young Women With Chronic Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06158802
Acronym
MC-HPV
Enrollment
223
Registered
2023-12-06
Start date
2024-01-23
Completion date
2025-06-26
Last updated
2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Condition, Human Papillomavirus Vaccine

Keywords

Human papillomavirus vaccine, Young women with chronic condition, Vaccination coverage rate

Brief summary

The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic disease and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease.

Detailed description

Girls and young women with chronic condition are at higher risk for infections that can be prevented by vaccination. Human papillomavirus infection is very common, one of the three most common in the general population. A vaccine exists to significantly prevent this infection and its complications. In France, it is advisable to vaccinate girls and boys from the age of 9 years and as soon as possible in the case of acquired immunodeficiency since these patients are more likely to be suffering from cancer induced by the human papillomavirus. In France, the overall rate of vaccination coverage for girls is 21%, which is significantly lower than in several other industrialized countries. The vaccination coverage rate for human papillomavirus in patients with chronic diseases may be even lower. The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic condition and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease.

Interventions

OTHERQuestionnaire

Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination. The questionnaire is completed by the patient.

Sponsors

URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
11 Years to 20 Years
Healthy volunteers
No

Inclusion criteria

* Information and non-opposition of major patients and holders of parental authority of minor patients and minor patients * Girls and young women aged 11 to 20 * To be followed at the Necker-Enfants Malades Hospital (chronic condition group) * To be followed at the Specialized Medical Center for Children and Adolescents (control group) * Have a chronic condition (chronic condition group) : * Diabetes type 1 * Metabolic diseases * Patients followed in immuno-hematology * Cystic Fibrosis * Sickle * Kidney transplant * Heart Disease * Inflammatory bowel diseases * Rare anorectal and pelvic anomalies * Live in France * Comprehension of the French language (oral and written)

Exclusion criteria

* Have a contraindication to the HPV vaccine - Gardasil 9 (Vidal Hoptimal, 2018) * Have a contraindication to the HPV vaccine - Gardasil (Vidal Hopitmal, 2018) * Have a contraindication to HPV vaccine - Cervarix (Vidal Hoptimal, 2018)

Design outcomes

Primary

MeasureTime frameDescription
Immunization coverage rate for human papillomavirus vaccineDay 1Percentage of patients with or without a chronic illness who have received HPV vaccination (complete vaccination schedule).

Secondary

MeasureTime frameDescription
Intention of vaccination by human papillomavirus vaccine by the usual health professionalsDay 1Percentage of patients with or without a chronic illness who have been offered HPV vaccination.
Category of health professionals offering vaccination by human papillomavirus vaccineDay 1Patients with or without a chronic illness to whom vaccination has been offered/prescribed : * Percentage of vaccination offered/prescribed by the general practitioner * Vaccination percentage proposed/prescribed by the pediatrician, * Vaccination percentage proposed/prescribed by the gynecologist, * Percentage of vaccination proposed/prescribed by the specialist doctor, * Percentage of vaccination offered/prescribed by another healthcare professional.
Reasons for non-vaccination by human papillomavirus vaccineDay 1Patients suffering from a chronic illness or not and not vaccinated: * Percentage of patients not vaccinated due to fear/apprehension, * Percentage of patients not vaccinated because they did not know this vaccine, * Percentage of patients not vaccinated because they are against vaccination, * Percentage of patients not vaccinated due to lack of time.
Description of parameters that may impact vaccination coverage for human papillomavirus vaccineDay 1Description of patients with or without a chronic illness and vaccinated or not against HPV * Average age of patients at the time of inclusion, * Socio-professional category of parents (father's and mother's profession), * Average age at menarche, * Assessment of risk behaviors (percentage of patients who smoke, percentage of patients who consume alcohol), * Percentage of patients who have started their sexual life, * Average age at first sexual intercourse, * Percentage of patients followed by a pediatrician, * Percentage of patients followed by a general practitioner, * Percentage of patients followed by a gynecologist.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026